eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | graft versus host disease |
| Comorbidity | C0376545|hematologic cancer |
| Sentences | 1 |
| PubMedID- 24475275 | In fact, maraviroc has been shown to inhibit chemotactic activity of lymphocytes and monocytes in vitro and to reduce the risk of graft-versus-host disease (gvhd) in patients with hematologic cancers after allogeneic hematopoietic stem cell transplantation [16], [30], [41]. |
Page: 1